Adam Green
Concepts (318)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Glioma | 21 | 2025 | 395 | 6.450 |
Why?
| | Central Nervous System Neoplasms | 9 | 2025 | 156 | 4.490 |
Why?
| | Brain Neoplasms | 23 | 2025 | 1238 | 4.450 |
Why?
| | Neoplasms | 10 | 2025 | 2671 | 1.970 |
Why?
| | Ependymoma | 4 | 2023 | 165 | 1.620 |
Why?
| | Hydrazines | 3 | 2025 | 35 | 1.560 |
Why?
| | Triazoles | 3 | 2025 | 147 | 1.430 |
Why?
| | Glioblastoma | 5 | 2021 | 345 | 1.250 |
Why?
| | Child | 38 | 2025 | 21935 | 1.160 |
Why?
| | Brain Stem Neoplasms | 4 | 2020 | 83 | 1.120 |
Why?
| | Neoplasm Recurrence, Local | 5 | 2025 | 1079 | 1.120 |
Why?
| | Karyopherins | 2 | 2019 | 19 | 1.090 |
Why?
| | Medical Oncology | 4 | 2024 | 289 | 1.020 |
Why?
| | Socioeconomic Factors | 8 | 2025 | 1289 | 1.010 |
Why?
| | Insurance Coverage | 2 | 2019 | 230 | 1.000 |
Why?
| | Cerebellar Neoplasms | 3 | 2023 | 152 | 0.980 |
Why?
| | Receptors, Cytoplasmic and Nuclear | 2 | 2019 | 220 | 0.950 |
Why?
| | Antineoplastic Agents | 7 | 2020 | 2129 | 0.940 |
Why?
| | Patient Care Bundles | 1 | 2025 | 23 | 0.940 |
Why?
| | Oncogene Proteins, Fusion | 3 | 2021 | 215 | 0.930 |
Why?
| | Protein-Arginine N-Methyltransferases | 1 | 2025 | 27 | 0.910 |
Why?
| | Rhabdomyosarcoma | 2 | 2024 | 72 | 0.860 |
Why?
| | Healthcare Disparities | 2 | 2021 | 654 | 0.850 |
Why?
| | Extracorporeal Membrane Oxygenation | 2 | 2024 | 301 | 0.830 |
Why?
| | Wilms Tumor | 1 | 2024 | 86 | 0.790 |
Why?
| | Germ-Line Mutation | 2 | 2021 | 172 | 0.780 |
Why?
| | Cross Infection | 1 | 2025 | 256 | 0.770 |
Why?
| | Radiation | 2 | 2021 | 24 | 0.770 |
Why?
| | Humans | 69 | 2025 | 137585 | 0.750 |
Why?
| | raf Kinases | 1 | 2021 | 13 | 0.750 |
Why?
| | Sarcoma, Ewing | 1 | 2022 | 97 | 0.700 |
Why?
| | Cancer Care Facilities | 1 | 2021 | 38 | 0.700 |
Why?
| | Proto-Oncogene Proteins c-cbl | 1 | 2021 | 12 | 0.700 |
Why?
| | Neoplasms, Germ Cell and Embryonal | 1 | 2022 | 77 | 0.680 |
Why?
| | Guideline Adherence | 1 | 2025 | 556 | 0.680 |
Why?
| | Neoplastic Stem Cells | 1 | 2025 | 399 | 0.680 |
Why?
| | Registries | 4 | 2024 | 2035 | 0.660 |
Why?
| | Intensive Care Units | 2 | 2025 | 827 | 0.650 |
Why?
| | Bone Neoplasms | 1 | 2022 | 247 | 0.640 |
Why?
| | Receptors, Nerve Growth Factor | 1 | 2019 | 17 | 0.640 |
Why?
| | MAP Kinase Signaling System | 1 | 2021 | 320 | 0.640 |
Why?
| | Meningeal Neoplasms | 1 | 2021 | 100 | 0.630 |
Why?
| | Kidney Neoplasms | 1 | 2024 | 403 | 0.620 |
Why?
| | Optic Nerve Neoplasms | 1 | 2019 | 11 | 0.620 |
Why?
| | Positron-Emission Tomography | 1 | 2021 | 294 | 0.620 |
Why?
| | Optic Chiasm | 1 | 2019 | 18 | 0.620 |
Why?
| | Retinoblastoma | 2 | 2016 | 32 | 0.610 |
Why?
| | Infant | 14 | 2024 | 9465 | 0.610 |
Why?
| | Sepsis | 1 | 2025 | 617 | 0.600 |
Why?
| | Adolescent | 17 | 2025 | 21513 | 0.590 |
Why?
| | Biomarkers, Tumor | 3 | 2020 | 1276 | 0.590 |
Why?
| | Combined Modality Therapy | 7 | 2021 | 1236 | 0.590 |
Why?
| | Blood-Brain Barrier | 4 | 2024 | 138 | 0.580 |
Why?
| | Gene Expression Regulation, Neoplastic | 8 | 2025 | 1396 | 0.580 |
Why?
| | Child, Preschool | 16 | 2025 | 11074 | 0.580 |
Why?
| | Craniopharyngioma | 1 | 2019 | 74 | 0.570 |
Why?
| | Choroid Plexus Neoplasms | 1 | 2017 | 8 | 0.570 |
Why?
| | Li-Fraumeni Syndrome | 1 | 2017 | 14 | 0.560 |
Why?
| | Everolimus | 1 | 2017 | 91 | 0.550 |
Why?
| | Clinical Trials as Topic | 2 | 2020 | 1050 | 0.550 |
Why?
| | Morpholines | 1 | 2017 | 122 | 0.530 |
Why?
| | Pituitary Neoplasms | 1 | 2019 | 190 | 0.530 |
Why?
| | Neuroimaging | 1 | 2019 | 259 | 0.520 |
Why?
| | Electric Stimulation Therapy | 1 | 2017 | 81 | 0.500 |
Why?
| | Prognosis | 8 | 2022 | 4030 | 0.500 |
Why?
| | Female | 34 | 2025 | 73304 | 0.500 |
Why?
| | Retinal Neoplasms | 1 | 2016 | 25 | 0.500 |
Why?
| | Male | 32 | 2025 | 67762 | 0.500 |
Why?
| | Microbubbles | 3 | 2024 | 49 | 0.490 |
Why?
| | NF-kappa B | 1 | 2019 | 691 | 0.480 |
Why?
| | Carcinoma | 1 | 2017 | 240 | 0.480 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2017 | 437 | 0.470 |
Why?
| | Cohort Studies | 7 | 2025 | 5742 | 0.470 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 3 | 2021 | 1692 | 0.460 |
Why?
| | Oxadiazoles | 1 | 2014 | 33 | 0.450 |
Why?
| | Neutropenia | 1 | 2015 | 146 | 0.450 |
Why?
| | Neoplasm Grading | 3 | 2021 | 307 | 0.450 |
Why?
| | Genetic Variation | 1 | 2019 | 991 | 0.440 |
Why?
| | Virilism | 1 | 2014 | 7 | 0.440 |
Why?
| | Active Transport, Cell Nucleus | 1 | 2014 | 124 | 0.440 |
Why?
| | Acrylamides | 1 | 2014 | 57 | 0.440 |
Why?
| | Thiazoles | 1 | 2014 | 123 | 0.440 |
Why?
| | Fathers | 1 | 2014 | 50 | 0.430 |
Why?
| | Fever | 1 | 2015 | 306 | 0.430 |
Why?
| | Cell Line, Tumor | 9 | 2025 | 3412 | 0.430 |
Why?
| | SEER Program | 3 | 2020 | 227 | 0.420 |
Why?
| | Delayed Diagnosis | 1 | 2014 | 91 | 0.420 |
Why?
| | Young Adult | 10 | 2025 | 13209 | 0.420 |
Why?
| | Rare Diseases | 1 | 2014 | 104 | 0.410 |
Why?
| | Histones | 4 | 2024 | 636 | 0.410 |
Why?
| | Adrenal Cortex Neoplasms | 1 | 2014 | 63 | 0.410 |
Why?
| | Adrenocortical Carcinoma | 1 | 2014 | 65 | 0.410 |
Why?
| | Proto-Oncogene Proteins B-raf | 3 | 2021 | 224 | 0.400 |
Why?
| | Retrospective Studies | 9 | 2025 | 15657 | 0.400 |
Why?
| | Protein-Tyrosine Kinases | 3 | 2020 | 434 | 0.390 |
Why?
| | DNA Copy Number Variations | 2 | 2023 | 182 | 0.360 |
Why?
| | United States | 11 | 2024 | 14841 | 0.360 |
Why?
| | Testosterone | 1 | 2014 | 409 | 0.330 |
Why?
| | Medulloblastoma | 2 | 2023 | 193 | 0.320 |
Why?
| | Drug Screening Assays, Antitumor | 2 | 2021 | 194 | 0.310 |
Why?
| | Infant, Newborn | 6 | 2020 | 6079 | 0.300 |
Why?
| | Social Class | 3 | 2023 | 282 | 0.300 |
Why?
| | Archaeology | 2 | 2025 | 39 | 0.290 |
Why?
| | Cell Proliferation | 4 | 2025 | 2475 | 0.280 |
Why?
| | Quality Improvement | 1 | 2015 | 1178 | 0.260 |
Why?
| | Proto-Oncogene Proteins | 2 | 2020 | 648 | 0.260 |
Why?
| | Teratoma | 2 | 2023 | 114 | 0.260 |
Why?
| | Gene Expression Profiling | 2 | 2024 | 1774 | 0.250 |
Why?
| | Rhabdoid Tumor | 2 | 2023 | 99 | 0.250 |
Why?
| | Survival Analysis | 2 | 2020 | 1325 | 0.250 |
Why?
| | Disease Progression | 2 | 2024 | 2757 | 0.250 |
Why?
| | Treatment Outcome | 6 | 2025 | 10811 | 0.250 |
Why?
| | Prospective Studies | 4 | 2024 | 7604 | 0.240 |
Why?
| | Autophagy | 2 | 2019 | 284 | 0.240 |
Why?
| | 12E7 Antigen | 1 | 2025 | 10 | 0.240 |
Why?
| | Astrocytoma | 2 | 2023 | 128 | 0.240 |
Why?
| | Anti-Bacterial Agents | 1 | 2015 | 1809 | 0.230 |
Why?
| | Sonication | 1 | 2024 | 13 | 0.230 |
Why?
| | Maximum Tolerated Dose | 1 | 2025 | 199 | 0.230 |
Why?
| | Mice | 9 | 2025 | 17787 | 0.210 |
Why?
| | Mutation | 6 | 2025 | 3958 | 0.210 |
Why?
| | Animals | 12 | 2025 | 36940 | 0.210 |
Why?
| | Receptors, Aryl Hydrocarbon | 1 | 2023 | 55 | 0.200 |
Why?
| | Carcinogenesis | 1 | 2025 | 217 | 0.200 |
Why?
| | Biology | 1 | 2024 | 88 | 0.200 |
Why?
| | Hodgkin Disease | 1 | 2024 | 138 | 0.200 |
Why?
| | Patient Selection | 2 | 2024 | 696 | 0.200 |
Why?
| | Case-Control Studies | 2 | 2023 | 3556 | 0.190 |
Why?
| | DNA Methylation | 3 | 2023 | 643 | 0.190 |
Why?
| | Adult | 7 | 2025 | 37929 | 0.190 |
Why?
| | Microglia | 1 | 2024 | 251 | 0.190 |
Why?
| | Preimplantation Diagnosis | 1 | 2021 | 7 | 0.190 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p15 | 1 | 2021 | 16 | 0.190 |
Why?
| | Cerebrospinal Fluid | 1 | 2022 | 92 | 0.190 |
Why?
| | Middle Aged | 7 | 2025 | 33479 | 0.180 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2017 | 2057 | 0.180 |
Why?
| | Magnetic Resonance Imaging | 5 | 2024 | 3566 | 0.180 |
Why?
| | Cardiopulmonary Resuscitation | 1 | 2024 | 249 | 0.180 |
Why?
| | Gene Ontology | 1 | 2021 | 53 | 0.180 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2021 | 69 | 0.180 |
Why?
| | Cause of Death | 1 | 2023 | 434 | 0.180 |
Why?
| | Gene Amplification | 1 | 2021 | 104 | 0.180 |
Why?
| | Receptor, Platelet-Derived Growth Factor alpha | 1 | 2021 | 44 | 0.180 |
Why?
| | Fertilization in Vitro | 1 | 2021 | 83 | 0.180 |
Why?
| | Mentors | 1 | 2023 | 202 | 0.180 |
Why?
| | Infusions, Intra-Arterial | 1 | 2021 | 59 | 0.170 |
Why?
| | Epigenesis, Genetic | 2 | 2023 | 660 | 0.170 |
Why?
| | Hematologic Neoplasms | 1 | 2023 | 156 | 0.170 |
Why?
| | Xenograft Model Antitumor Assays | 3 | 2025 | 872 | 0.170 |
Why?
| | Geography | 1 | 2021 | 200 | 0.170 |
Why?
| | Cell Differentiation | 3 | 2020 | 1991 | 0.170 |
Why?
| | Leukocytes | 1 | 2022 | 311 | 0.170 |
Why?
| | Heart Arrest | 1 | 2024 | 339 | 0.170 |
Why?
| | Hospital Mortality | 1 | 2025 | 911 | 0.170 |
Why?
| | Benzamides | 2 | 2019 | 216 | 0.170 |
Why?
| | Cell Survival | 3 | 2019 | 1120 | 0.170 |
Why?
| | Cyclophosphamide | 1 | 2021 | 247 | 0.170 |
Why?
| | Polycomb Repressive Complex 1 | 1 | 2020 | 50 | 0.170 |
Why?
| | Zinc | 1 | 2023 | 297 | 0.170 |
Why?
| | Receptor, EphB4 | 1 | 2020 | 34 | 0.170 |
Why?
| | Computer Simulation | 2 | 2021 | 978 | 0.170 |
Why?
| | Ephrin-B2 | 1 | 2020 | 47 | 0.170 |
Why?
| | Multifactorial Inheritance | 1 | 2021 | 174 | 0.170 |
Why?
| | Genes, myc | 1 | 2020 | 48 | 0.160 |
Why?
| | Recurrence | 1 | 2023 | 1060 | 0.160 |
Why?
| | Transcriptional Elongation Factors | 1 | 2020 | 40 | 0.160 |
Why?
| | Social Determinants of Health | 1 | 2024 | 267 | 0.160 |
Why?
| | Critical Illness | 2 | 2023 | 811 | 0.160 |
Why?
| | Neoplasms, Neuroepithelial | 1 | 2019 | 16 | 0.160 |
Why?
| | Eye Enucleation | 2 | 2016 | 12 | 0.160 |
Why?
| | Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2023 | 289 | 0.160 |
Why?
| | Pedigree | 1 | 2021 | 514 | 0.160 |
Why?
| | Immunophenotyping | 1 | 2021 | 318 | 0.160 |
Why?
| | Time Factors | 2 | 2024 | 6828 | 0.160 |
Why?
| | Pyrimidinones | 1 | 2020 | 113 | 0.150 |
Why?
| | Anemia, Sickle Cell | 1 | 2023 | 270 | 0.150 |
Why?
| | Age Distribution | 1 | 2020 | 392 | 0.150 |
Why?
| | Protein Domains | 1 | 2021 | 289 | 0.150 |
Why?
| | Sex Distribution | 1 | 2020 | 375 | 0.150 |
Why?
| | Sirolimus | 1 | 2021 | 276 | 0.150 |
Why?
| | Blood Coagulation Disorders | 1 | 2021 | 173 | 0.150 |
Why?
| | Deoxycytidine | 1 | 2020 | 179 | 0.150 |
Why?
| | Aged | 5 | 2025 | 23961 | 0.150 |
Why?
| | Models, Genetic | 1 | 2021 | 600 | 0.150 |
Why?
| | Respiration, Artificial | 1 | 2023 | 645 | 0.150 |
Why?
| | Influenza Vaccines | 1 | 2023 | 539 | 0.150 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2024 | 1477 | 0.150 |
Why?
| | Genetic Testing | 1 | 2021 | 460 | 0.150 |
Why?
| | Antibodies, Monoclonal | 1 | 2025 | 1430 | 0.140 |
Why?
| | Tumor Microenvironment | 1 | 2022 | 674 | 0.140 |
Why?
| | Tomography, X-Ray Computed | 2 | 2019 | 2691 | 0.140 |
Why?
| | Crohn Disease | 1 | 2021 | 243 | 0.140 |
Why?
| | Cognitive Dysfunction | 1 | 2023 | 383 | 0.140 |
Why?
| | Pyrimidines | 2 | 2019 | 470 | 0.140 |
Why?
| | Genes, p53 | 1 | 2017 | 72 | 0.140 |
Why?
| | Adaptor Proteins, Signal Transducing | 1 | 2020 | 430 | 0.140 |
Why?
| | Mechanistic Target of Rapamycin Complex 2 | 1 | 2017 | 62 | 0.140 |
Why?
| | Schizophrenia | 1 | 2021 | 439 | 0.130 |
Why?
| | Transfection | 1 | 2019 | 945 | 0.130 |
Why?
| | Mechanistic Target of Rapamycin Complex 1 | 1 | 2017 | 125 | 0.130 |
Why?
| | Prevalence | 1 | 2024 | 2734 | 0.130 |
Why?
| | Phosphorylation | 2 | 2020 | 1759 | 0.130 |
Why?
| | Chloroquine | 1 | 2017 | 54 | 0.130 |
Why?
| | Epigenomics | 3 | 2023 | 115 | 0.130 |
Why?
| | Mortality | 1 | 2019 | 362 | 0.130 |
Why?
| | Macrophages | 1 | 2024 | 1547 | 0.130 |
Why?
| | Pyrazoles | 1 | 2020 | 423 | 0.130 |
Why?
| | Inflammation | 2 | 2024 | 2837 | 0.130 |
Why?
| | Radiotherapy | 1 | 2017 | 201 | 0.130 |
Why?
| | Immunotherapy | 1 | 2021 | 641 | 0.120 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2019 | 539 | 0.120 |
Why?
| | Cell Cycle Proteins | 1 | 2020 | 617 | 0.120 |
Why?
| | Anticoagulants | 1 | 2021 | 664 | 0.120 |
Why?
| | Pons | 1 | 2015 | 26 | 0.120 |
Why?
| | Molecular Targeted Therapy | 2 | 2017 | 411 | 0.120 |
Why?
| | Phenotype | 1 | 2024 | 3196 | 0.120 |
Why?
| | Cell Culture Techniques | 1 | 2017 | 363 | 0.120 |
Why?
| | Transcriptome | 1 | 2021 | 971 | 0.120 |
Why?
| | Macaca fascicularis | 1 | 2014 | 65 | 0.110 |
Why?
| | Apoptosis | 3 | 2025 | 2553 | 0.110 |
Why?
| | Cell Cycle | 1 | 2017 | 601 | 0.110 |
Why?
| | Risk Factors | 3 | 2021 | 10388 | 0.110 |
Why?
| | Stroke | 1 | 2023 | 1120 | 0.110 |
Why?
| | Adrenalectomy | 1 | 2014 | 68 | 0.110 |
Why?
| | Mutism | 1 | 2014 | 6 | 0.110 |
Why?
| | Cell Cycle Checkpoints | 1 | 2014 | 98 | 0.110 |
Why?
| | Leukemia, Myeloid, Acute | 1 | 2021 | 630 | 0.110 |
Why?
| | Administration, Cutaneous | 1 | 2014 | 129 | 0.110 |
Why?
| | Insurance, Health | 1 | 2016 | 283 | 0.110 |
Why?
| | Indoles | 1 | 2017 | 412 | 0.100 |
Why?
| | Chemoradiotherapy | 1 | 2015 | 225 | 0.100 |
Why?
| | Infratentorial Neoplasms | 1 | 2014 | 63 | 0.100 |
Why?
| | Precision Medicine | 1 | 2017 | 429 | 0.100 |
Why?
| | Sulfonamides | 1 | 2017 | 513 | 0.100 |
Why?
| | Diagnostic Errors | 1 | 2014 | 170 | 0.100 |
Why?
| | Dexamethasone | 1 | 2014 | 368 | 0.090 |
Why?
| | Hydrocortisone | 1 | 2014 | 322 | 0.090 |
Why?
| | Drug Resistance, Neoplasm | 1 | 2017 | 801 | 0.090 |
Why?
| | Drug Delivery Systems | 2 | 2024 | 365 | 0.090 |
Why?
| | Brain | 4 | 2024 | 2668 | 0.080 |
Why?
| | Weight Gain | 1 | 2014 | 519 | 0.080 |
Why?
| | Survival Rate | 3 | 2021 | 1972 | 0.080 |
Why?
| | Aging | 1 | 2020 | 1864 | 0.080 |
Why?
| | Follow-Up Studies | 2 | 2019 | 5131 | 0.080 |
Why?
| | Rats, Sprague-Dawley | 1 | 2014 | 2486 | 0.080 |
Why?
| | Patient Education as Topic | 1 | 2014 | 766 | 0.080 |
Why?
| | Electronic Health Records | 1 | 2015 | 1069 | 0.070 |
Why?
| | Longitudinal Studies | 1 | 2014 | 2844 | 0.060 |
Why?
| | Chromatin | 2 | 2020 | 519 | 0.060 |
Why?
| | History, Ancient | 1 | 2025 | 54 | 0.060 |
Why?
| | Ultrasonic Waves | 1 | 2024 | 6 | 0.060 |
Why?
| | Receptors, CCR1 | 1 | 2024 | 4 | 0.060 |
Why?
| | Receptors, CCR5 | 1 | 2024 | 56 | 0.060 |
Why?
| | Agriculture | 1 | 2025 | 103 | 0.050 |
Why?
| | Predictive Value of Tests | 2 | 2021 | 2031 | 0.050 |
Why?
| | Histology | 1 | 2023 | 4 | 0.050 |
Why?
| | Mice, Inbred C57BL | 2 | 2024 | 5757 | 0.050 |
Why?
| | Chromosomes, Human, Pair 10 | 1 | 2023 | 19 | 0.050 |
Why?
| | Caco-2 Cells | 1 | 2023 | 77 | 0.050 |
Why?
| | Myeloid Cells | 1 | 2024 | 148 | 0.050 |
Why?
| | Chromosomes, Human, Pair 1 | 1 | 2023 | 71 | 0.050 |
Why?
| | Particle Size | 1 | 2024 | 394 | 0.050 |
Why?
| | Cytosol | 1 | 2023 | 226 | 0.050 |
Why?
| | Research Personnel | 1 | 2024 | 173 | 0.050 |
Why?
| | Hematopoietic Stem Cell Transplantation | 1 | 2008 | 622 | 0.050 |
Why?
| | Career Choice | 1 | 2024 | 219 | 0.050 |
Why?
| | Organic Chemicals | 1 | 2023 | 124 | 0.050 |
Why?
| | Mitosis | 1 | 2023 | 192 | 0.050 |
Why?
| | Cerebellum | 1 | 2023 | 224 | 0.050 |
Why?
| | Contrast Media | 1 | 2024 | 467 | 0.050 |
Why?
| | Surveys and Questionnaires | 2 | 2024 | 5778 | 0.040 |
Why?
| | Cytoreduction Surgical Procedures | 1 | 2021 | 63 | 0.040 |
Why?
| | Ligands | 1 | 2023 | 664 | 0.040 |
Why?
| | Chromosome Deletion | 1 | 2021 | 115 | 0.040 |
Why?
| | Immunization | 1 | 2023 | 411 | 0.040 |
Why?
| | Ubiquitin Thiolesterase | 1 | 2021 | 48 | 0.040 |
Why?
| | Sequence Analysis, RNA | 1 | 2023 | 452 | 0.040 |
Why?
| | Gene Rearrangement | 1 | 2021 | 150 | 0.040 |
Why?
| | Neoplasm Staging | 1 | 2024 | 1389 | 0.040 |
Why?
| | Cluster Analysis | 1 | 2021 | 499 | 0.040 |
Why?
| | Dendritic Cells | 1 | 2023 | 483 | 0.040 |
Why?
| | Hospitals | 1 | 2024 | 691 | 0.040 |
Why?
| | Administration, Oral | 1 | 2021 | 816 | 0.040 |
Why?
| | Kaplan-Meier Estimate | 1 | 2021 | 889 | 0.040 |
Why?
| | Tumor Suppressor Proteins | 1 | 2021 | 327 | 0.040 |
Why?
| | Genome, Human | 1 | 2021 | 425 | 0.040 |
Why?
| | Aminopyridines | 1 | 2019 | 98 | 0.040 |
Why?
| | Sex Factors | 1 | 2024 | 2071 | 0.040 |
Why?
| | Neoplasm Invasiveness | 1 | 2020 | 510 | 0.040 |
Why?
| | Mice, Nude | 1 | 2020 | 698 | 0.040 |
Why?
| | Tumor Cells, Cultured | 1 | 2020 | 955 | 0.040 |
Why?
| | Lysine | 1 | 2020 | 294 | 0.040 |
Why?
| | Health Personnel | 1 | 2024 | 710 | 0.040 |
Why?
| | RNA-Binding Proteins | 1 | 2021 | 422 | 0.030 |
Why?
| | Blotting, Western | 1 | 2019 | 1226 | 0.030 |
Why?
| | Venous Thromboembolism | 1 | 2021 | 316 | 0.030 |
Why?
| | Enzyme Inhibitors | 1 | 2020 | 840 | 0.030 |
Why?
| | Pediatrics | 1 | 2024 | 1101 | 0.030 |
Why?
| | Hemorrhage | 1 | 2021 | 722 | 0.030 |
Why?
| | Drug Synergism | 1 | 2017 | 382 | 0.030 |
Why?
| | Pandemics | 1 | 2024 | 1639 | 0.030 |
Why?
| | Cell Movement | 1 | 2020 | 967 | 0.030 |
Why?
| | Flow Cytometry | 1 | 2019 | 1178 | 0.030 |
Why?
| | Protein Kinase Inhibitors | 1 | 2021 | 916 | 0.030 |
Why?
| | Vaccination | 1 | 2023 | 1381 | 0.030 |
Why?
| | Transcription Factors | 1 | 2023 | 1719 | 0.030 |
Why?
| | Transcription, Genetic | 1 | 2021 | 1457 | 0.030 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2023 | 1329 | 0.030 |
Why?
| | Mice, Transgenic | 1 | 2020 | 2167 | 0.030 |
Why?
| | Hospitalization | 1 | 2024 | 2199 | 0.030 |
Why?
| | Disease Models, Animal | 1 | 2024 | 4295 | 0.030 |
Why?
| | Cross-Sectional Studies | 1 | 2024 | 5472 | 0.030 |
Why?
| | Genetic Predisposition to Disease | 1 | 2021 | 2426 | 0.020 |
Why?
| | Health Status Disparities | 1 | 2015 | 289 | 0.020 |
Why?
| | Risk Assessment | 1 | 2021 | 3457 | 0.020 |
Why?
| | Pregnancy | 1 | 2021 | 6763 | 0.020 |
Why?
| | Signal Transduction | 1 | 2021 | 5079 | 0.020 |
Why?
| | Transplantation, Autologous | 1 | 2008 | 238 | 0.020 |
Why?
|
|
Green's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|